Category Archives: Market Intelligence

Market Intelligence

Knowsource.com Announces Transition to Access Market Intelligence

Posted on by John Santilli

I’ve mentioned the rapid changes in the healthcare and pharmaceutical industries that are impacting our sector and how we conduct business within its landscape. Because of the changes I’ve seen coming, I asked for your feedback in a survey to determine what concerns you have with these changes and the best course of action to […]

Continue reading →
Market Intelligence

Hepatitis C and Specialty Pharmacy Market

Posted on by Dr. Randy

Express Scripts Plans a Specialty Drug Price War over new hepatitis C treatments reports a recent Bloomberg News story. The news follows the release of Gilead’s Sovaldi (sofosbuvir), which reportedly costs $1,000 per pill. Express Scripts projects that Hepatitis C drug trend will grow by 168% by 2015, so employers and health plan payers are […]

Continue reading →
Market Intelligence

Tier 2 is Dead!

Posted on by Dr. Randy

It’s not just Health Care Reform that is turning the world of health care upside down. The cost shift to both the employee/consumer is dramatic and having an effect on sales. The old paradigm of success being defined as having Tier 2 access is no longer valid. The out of pocket burden for the employee/consumer […]

Continue reading →
Market Intelligence

Contracting With Specialty Pharmacies (SPs) At Your Own Peril

Posted on by Dr. Randy

How a company works with and contracts with SPs will have to be rethought as a result of the initial Department of Justice (DoJ) settlement with BioScrip and ongoing investigation of Novartis in their marketing practices. When Novartis launched Exjade, it created a limited distribution network, including BioScrip and two other specialty pharmacies selected by […]

Continue reading →
Market Intelligence

Walgreens Specialty Pharmacy Exclusive Distributor for Three Sigma-Tau Drugs

Posted on by AMI
01
Aug

The deal includes Sigma-Tau’s Adagen (pegademase bovine), Cystaran (cysteamine ophthalmic solution), and Matulane (procarbazine hydrochloride). As a result of the agreement, each of these prescription drugs can now be obtained through Walgreens Specialty Pharmacy locations. Adagen is an intramuscular injection indicated for replacement therapy for adenosine deaminase (ADA) deficiency in patients with severe combined immunodeficiency […]

Continue reading →
Market Intelligence

Onco360 to distribute Gilead Sciences’ Zydelig

Posted on by AMI
28
Jul

Onco360 recently announced that it has been selected to be part of the limited network to distribute Gilead Sciences’ Zydelig (idelalisib) tablets. Onco360 is one of the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services companies. It will now be part of the highly limited Specialty Pharmacy network of Zydelig tablets, which has just […]

Continue reading →
Market Intelligence

ACA is Limiting Patient Access to Cancer Centers

Posted on by Dr. Randy

Some of America’s best cancer hospitals are off-limits to many of the people now signing up for coverage under the nation’s new health care program, according to a recent story in the Washington Post. An Associated Press survey found examples coast to coast. Seattle Cancer Care Alliance is excluded by five out of eight insurers […]

Continue reading →